---
figid: PMC7873600__fonc-10-539527-g002
figlink: pmc/articles/PMC7873600/figure/f2/
number: F2
caption: Combination of targeted therapy with immunotherapy or chemotherapy in bladder
  cancer. FGFR and PI3K/AKT/mTOR signing pathways are potential targets in bladder
  cancer. Blocking FGFR or PI3K/AKT/mTOR pathway decreased PD-L1 levels and increased
  immunotherapy response. On the other hand, these targeted drugs increased the pro-apoptotic
  effect and cytotoxic effect of chemotherapy drugs.
pmcid: PMC7873600
papertitle: Novel Combination Therapies for the Treatment of Bladder Cancer.
reftext: Mei Peng, et al. Front Oncol. 2020;10:539527.
pmc_ranked_result_index: '6706'
pathway_score: 0.9573104
filename: fonc-10-539527-g002.jpg
figtitle: Combination of targeted therapy with immunotherapy or chemotherapy in bladder
  cancer
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7873600__fonc-10-539527-g002.html
  '@type': Dataset
  description: Combination of targeted therapy with immunotherapy or chemotherapy
    in bladder cancer. FGFR and PI3K/AKT/mTOR signing pathways are potential targets
    in bladder cancer. Blocking FGFR or PI3K/AKT/mTOR pathway decreased PD-L1 levels
    and increased immunotherapy response. On the other hand, these targeted drugs
    increased the pro-apoptotic effect and cytotoxic effect of chemotherapy drugs.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FGFR4
  - FGFRL1
  - FGFR1
  - FGFR3
  - FGFR2
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - AKT2
  - AKT3
  - AKT1
  - CD274
  - MTOR
  - tyrosine
  - Everolimus
genes:
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR4
  entrez: '2264'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFRL1
  entrez: '53834'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR1
  entrez: '2260'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR3
  entrez: '2261'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR2
  entrez: '2263'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
chemicals:
- word: tyrosine
  source: ''
  identifier: ''
- word: Everolimus
  source: MESH
  identifier: C107135
diseases: []
figid_alias: PMC7873600__F2
redirect_from: /figures/PMC7873600__F2
figtype: Figure
---
